Emerging studies suggest Retatrutide , a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , may provide a notable development for body loss . Preliminary patient investigations have indicated impressive reductions in body tissue, possibly outperforming existing weight-loss medications . Despite this, additional